The wet AMD market is dominated by three therapies—Roche / Genentech / Novartis’s Lucentis, approved for wet AMD, Roche / Genentech / Chugai’s Avastin, approved for cancer but commonly compounded and used off-label for wet AMD, and Regeneron / Bayer HealthCare / Santen’s Eylea, which has experienced strong and continued uptake at the expense of the other VEGF inhibitors. Although the majority of AMD patients are diagnosed with the dry form of AMD, management of this disease type is limited to minimally effective vitamin formulations because no prescription pharmacotherapies are approved for this large and underserved subpopulation. While the bulk of emerging therapies target wet AMD patients because the pathology presents clearer drug targets, there are a small number of novel therapies being tested in patients with the dry form of AMD—an indication that has been plagued by several Phase III failures.

Questions Answered:

  • Do KOLs perceive any differences between the mainstays Avastin, Eylea, and Lucentis? How is their use expected to change, if at all, over the next ten years?
  • Biosimilar versions of Eylea and Lucentis are forecast to launch within the next five years. What is the likely impact of these therapies on current and emerging VEGF inhibitors?
  • A substantial unmet need in wet AMD exists for therapies with longer dosing intervals than offered by current therapies. To what extent are the new and emerging VEGF inhibitors brolucizumab (Beovu; Novartis), abicipar pegol (Allergan), the ranibizumab port delivery system (Roche), and conbercept (Chengdu Kanghong Biotech) as well as the emerging VEGF / Ang-2 inhibitor faricimab (Roche) expected to capitalize on this unmet need?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 18 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other DRG research.

Epidemiology: Total prevalence of late AMD by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.

Forecast: Ten-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies, segmented by brands / biosimilars and epidemiological subpopulations.

Emerging therapies: Phase III/PR: 7 drugs; Phase II/III: 1 drug; key early-phase therapies.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Dry and Wet Age-Related Macular Degeneration - Key Findings - November 2019
    • Key Updates
      • November 2019
      • October 2019
      • September 2019
      • June 2019
      • February 2019
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for AMD?
        • What Factors Are Constraining the Market for AMD?
      • Drug Class-Specific Trends
        • VEGF Inhibitors
        • VEGF / Ang-2 Inhibitors
        • Complement System Inhibitors
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions - Dry and Wet Age-Related Macular Degeneration (2018-2028) - November 2019
      • Market Forecast Dashboard - Dry and Wet Age-Related Macular Degeneration (2018-2028) - November 2019
    • Etiology and Pathophysiology
      • Disease Overview
      • Pathophysiology
        • Disease Classifications
        • Anatomy of the Eye
        • Pathology
      • Etiology
      • Risk Factors
        • Genetic Risk Factors
        • Other Risk Factors
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases: Late AMD
        • Total Prevalent Cases: GA and Wet AMD
        • Diagnosed Prevalent Cases of Late AMD
        • Drug-Treated Prevalent Cases of Late AMD
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • VEGF Inhibitors
        • Photosensitizing Agents
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in AMD
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • VEGF Inhibitors
        • VEGF / Ang-2 Inhibitors
        • Complement System Inhibitors
        • Retinoids
        • Cell-Based Therapies
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Market Forecast Assumptions File
      • Bottom-Up Forecasting Overview
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Dry and Wet AMD Bibliography

Author(s): Natalie Taylor, PhD; Emma McFadden, PhD; Shefali Gulati, MBA Pharm; Deepti Sharma, MPH

Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.

Emma McFadden, is a  Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and ; Prior to joining Decision Resources Group, Emma earned a in neuroscience and a in biochemistry from Trinity College Dublin.  

Shefali Gulati, Associate analyst, is part of the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She comes with one year of experience working on multiple client projects revolving around opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds a MBA degree in Pharmaceutical Management from the National Institute of Pharmaceutical Education and Research (NIPER) in India and Bachelor’s in Pharmacy from DIPSAR.

Deepti started working with Decision Resources Group as an intern in early 2017 and currently works as an associate works with a team of global epidemiologists in providing robust forecast estimates for multiple indications. Deepti holds a Master’s in Public Health degree from PGIMER School of Public Health, and a bachelor’s degree in dental surgery from HP Government Dental College from Himachal Pradesh University, India.  

Related Reports

Dry and Wet Age-Related Macular Degeneration | Access & Reimbursement | Detailed, Expanded Analysis: Special Focus on Retinal Therapies: US Payer Management of the Medical Benefit

As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to i...

View Details

Dry and Wet Age-Related Macular Degeneration | Special Topics | Special Topics: Biosimilar Anti-VEGF Agents (US)

The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retin...

View Details